The FDA approved Exact Sciences’ Cologuard Plus multitarget stool DNA test to screen adults aged 45 years or older at average risk for colorectal cancer, according to a company press release. Compared ...

The Food and Drug Administration (FDA) has approved the Cologuard Plus™ test for colorectal cancer screening in adults aged 45 years and older who are at average risk for colorectal cancer. According ...

SHREVEPORT, La. -- No one likes to get a colonoscopy, but it's an important tool in the fight against colon cancer. There is an easier way: Cologuard is a non-invasive, effective, and affordable ...

Colon cancer is the second-deadliest cancer in America. It's not deadly because it's particularly hard to treat or because oncologists are bad at spotting it. In large part, it's because people aren't ...

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the U.S. Food and Drug Administration (FDA) approved ...

Exact Sciences announced the results of its DeeP-C clinical study comparing the efficacy of Cologuard, a multi-target stool DNA-based screening test, to the fecal immunochemical test. • Cologuard ...

Data demonstrate long-term impact of the Cologuard test, a powerful tool for preventing and detecting cancer The data assessed the far-reaching benefits of the first and only multi-target stool DNA ...

Colon cancer is the second-deadliest cancer in the US, partly due to low screening rates. New and emerging screening tools, like blood and breath tests, may offer alternatives to in-office screenings.

Last week, shares of Cologuard dropped following a U.S. Preventative Services Task Force rating announcement. But, a new study of patient preferences could affect the USPSTF’s final recommendations, ...